Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

bioAffinity Technologies Inc

BIAF ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Micro Cap Analyst: N/A

Last Close

$0.40

▲ +4.99%

Market Cap $3.26M · Vol 25.36K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.26M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

17.32

Momentum

Beta

-1.17

vs Market

52W High

$13.50

97.02% below

52W Low

$0.35

14.36% above

Volume

25.36K

Avg 33.34K

P/B

0.73

Price-to-book

ROE

N/A

Return on equity

Free Float

98.19%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, bioAffinity Technologies Inc (BIAF) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BIAF pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-21.16%

-43.32%

-79.79%

-61.34%

YTD

-65.92%

-94.75%

-99.28%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$6.16M
Net Income	$-14,909,750.00
Revenue Growth (YoY)	+18.99%
Gross Margin	23.21%
Operating Margin	-171.58%
Net Profit Margin	-241.96%
ROE	N/A
ROA · ROIC	-170.14% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.33
P/B	0.73
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	8.10M

Technical Indicators

50-Day SMA	$0.84
200-Day SMA	$1.60
RSI (14)	17.32
Beta	-1.17
52-Week High	$13.50
52-Week Low	$0.35

Volume Today	25.36K
Avg Daily Volume (30D)	33.34K
Relative Volume	0.76x
Volatility (10D)	101.61
Volatility (30D)	82.71
Free Float	98.19%

Analyst Consensus

N/A

Current Price $0.40

Mean Target N/A

52W Low$0.35 52W High$13.50

Current

Target

$0.35 $13.50

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00H69JDY0

ISINUS09076W3079

CountryUnited States of America

Sub-IndustryLaboratory Diagnostic & Testing Substances

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

GH Guardant Health Inc -1.46% BIM.PA Biomerieux SA +0.14% TXG 10X Genomics Inc -3.54% LNTH Lantheus Holdings Inc +0.01% CAI Caris Life Sciences Inc -1.71%

Company Profile

bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.